Recursion Pharmaceuticals– tag –
-
Isomorphic Labs and Recursion Pharmaceuticals Forge Major AI Drug Discovery Alliances with Pharma Giants
flcube.com International Overview Isomorphic Labs, an Alphabet subsidiary, has secured significant AI-driven drug discovery partnerships with Eli Lilly and Novartis to identify novel small molecule therapeutics for undisclosed targets. C... -
Recursion Pharmaceuticals Reports Q2 Revenue Pressure but Advances First AI-Designed Neuroscience Target with Genentech to Early Discovery
Simply Wall St USA Overview Recursion Pharmaceuticals (RXRX) reported Q2 2026 revenue pressures and ongoing losses but highlighted a significant milestone: its first neuroscience target, identified through its AI drug discovery platform ... -
Mapping AI Drug Discovery: Key Players Lead Across Target Identification, Generative Design, and Clinical Optimization
Unknown Global Overview A new article maps the AI drug discovery landscape into four key layers: biological target identification, generative molecule design, automated experimentation, and clinical trial optimization. Recursion Pharmace... -
Recursion Pharmaceuticals Initiates Phase 1 Clinical Trial for AI-Designed Cancer Candidate Drug
ClinicalTrials.gov USA Overview Recursion Pharmaceuticals has registered a novel Phase 1 clinical trial (NCTxxxxxxx) for an AI-designed small molecule cancer candidate drug in patients with advanced solid tumors. This trial will evaluate...
1